TWD
IONS icon

True Wealth Design’s Ionis Pharmaceuticals IONS Stock Holding History

True Wealth Design’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$556 Hold
7
– – ﹤0.01% 2172
2026
Q1 		$526 Hold
7
– – ﹤0.01% 2030
2025
Q4 		$554 Hold
7
– – ﹤0.01% 1920
2025
Q3 		$458 Hold
7
– – ﹤0.01% 2038
2025
Q2 		$277 Sell
7
-6
-46% -$196 ﹤0.01% 1973
2025
Q1 		$393 Buy
+13
New +$426 ﹤0.01% 1652

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

True Wealth Design's IONS Position: Q2 2026 in Review

True Wealth Design held its Ionis Pharmaceuticals (IONS) position steady in Q2 2026 at 7 shares worth $556. The position accounts for ﹤0.01% of the portfolio, ranked #2172.

True Wealth Design first reported a position in IONS in Q1 2025 and has held it in 6 quarters since. 513 funds tracked by Wall St. Rank hold IONS as of Q2 2026.

  • True Wealth Design held 7 shares of Ionis Pharmaceuticals worth $556 as of Q2 2026.
  • True Wealth Design left its Ionis Pharmaceuticals share count unchanged in Q2 2026.
  • Ionis Pharmaceuticals made up ﹤0.01% of True Wealth Design's portfolio in Q2 2026, its #2172 holding.
  • True Wealth Design first reported a position in Ionis Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
  • 513 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.

Based on True Wealth Design's 13F filing for Q2 2026, filed 16 Jul 2026.